Literature DB >> 12115844

Solubility of E2050 at various pH: a case in which apparent solubility is affected by the amount of excess solid.

Zeren Wang1, Lana S Burrell, William J Lambert.   

Abstract

The solubility of E2050, supplied as a dihydrochloride salt, in aqueous solutions at different pHs was studied. Two pK(a)s controlling the equilibrium between the various protonated species were determined. The solubility-pH profile of E2050 is expected to be high in acidic solutions because protonated species are formed and to be low in alkaline conditions due to the formation of hydrophobic free base. The solubility is also affected by chloride ion, a common ion for this drug substance. Two solubility products (K(sp)) were determined corresponding to the solubility of di-HCl salt and mono-HCl salt. Based on the pK(a)s (3.10 and 7.71), the solubility products with chloride (2.92 and 3.77 as corresponding pK(sp)), and the solubility of free base (2 x 10(-5) M), the solubility in solutions with different pH and different levels of chloride ion can be predicted. The prediction of the solubility change during the dilution of E2050 parenteral formulations by saline was also demonstrated. Furthermore, the present study presents an interesting example in which an apparent solubility can be different if varying (excess) amounts of salt are added to the solution. In this case, excess chloride ion suppresses the solubility in the pH region where mono-HCl salt controls the solubility. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115844     DOI: 10.1002/jps.10107

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Solubility of pioglitazone hydrochloride in binary and ternary mixtures of water, propylene glycol, and polyethylene glycols 200, 400, and 600 at 298.2 k.

Authors:  Abolghasem Jouyban; Shahla Soltanpour
Journal:  AAPS PharmSciTech       Date:  2010-11-30       Impact factor: 3.246

2.  Impact of the amount of excess solids on apparent solubility.

Authors:  Kohsaku Kawakami; Kyoko Miyoshi; Yasuo Ida
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: the case of indomethacin.

Authors:  Deepak Bahl; Robin H Bogner
Journal:  AAPS PharmSciTech       Date:  2008-01-19       Impact factor: 3.246

4.  Incorporation of physiologically based pharmacokinetic modeling in the evaluation of solubility requirements for the salt selection process: a case study using phenytoin.

Authors:  Po-Chang Chiang; Harvey Wong
Journal:  AAPS J       Date:  2013-08-14       Impact factor: 4.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.